(1). Such guidance shall take into account the least burdensome requirements under subsection (c). (g) Practice of medicine Nothing in this subchapter shall be construed to limit or interfere with the authority of a health care practitioner to prescribe or administer any lawfully offered in vitro clinical test for any condition or disease within a legitimate health care practitioner-patient relationship pursuant to applicable Federal or State law. (h) Sale, distribution, labeling Nothing in this section shall be construed to limit the authority of the Secretary to establish or enforce restrictions on the sale, distribution, or labeling of an in vitro clinical test under this Act. (i) Promotion of unapproved uses Nothing in this section shall be construed to alter any prohibition on the promotion of unapproved uses of legally offered in vitro clinical tests. (j) Voluntary submissions Nothing in section 587C shall be construed to prevent a developer developing a test described in such section, including an academic medical center laboratory described in subsection (a)(7) of such section, from filing an application under section 587B or section 587D, or from adhering to the requirements of section 587K with regard to a test protocol described in section 587K or for any other test or use of a test. 587BB. Judicial review (a) In general Not later than 30 days after an order issued pursuant to section 587B or 587D, any person adversely affected by such order may file a petition with the United States Court of Appeals for the District of Columbia or for the circuit wherein such person resides or has a principal place of business for judicial review of such order, in accordance with the procedure set forth in section 517(a). (b) Application of provisions Subsections (a) through (e) of section 517 shall apply with respect to a petition under subsection (a) of this section in the same manner such subsections apply to a petition under section 517. Subsection (f) of section 517 shall apply to an order issued under section